ALT
Altimmune, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-06
Figures on this page computed 2026-11-08 12:40 UTC
Last close
1.97USD
Market data, 2026-11-05
Except where said otherwise: 10-K for 2025, filed 2026-03-06
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-06
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
- 10-K for 2025, filed 2026-03-06
- 10-K for 2025, filed 2026-03-06
- 10-K for 2025, filed 2026-03-06
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-06
- 10-Q for 2025, filed 2026-08-12
-214861.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
- 10-K for 2025, filed 2026-03-06
- 10-K for 2025, filed 2026-03-06
-164746.3%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
- 10-K for 2025, filed 2026-03-06
- 10-K for 2025, filed 2026-03-06
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
- 10-K for 2025, filed 2026-03-06
- 10-Q for 2025, filed 2026-08-12
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Growth is the furthest below its sector's middle: 0.26 against 0.50 on the market's range.
- Growth-65.3%26 of 100, below its sector
- Returns on capital-39.2%20 of 100, at its sector
- Margins-230461.0%0 of 100, below its sector
- Price0.8x38 of 100, at its sector
- Safety18.5559 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 2 of 2- Profit on each unit of sales-214,861%-4,881%Behind
Higher is better here.
- Return on the capital it usesn/an/an/a
Higher is better here.
- Sales growth over five years-65.3%-36.8%Behind
Higher is better here.
- Debt against equityn/an/an/a
Lower is better here.
- Gross marginn/an/an/a
Higher is better here.
- Price against earningsn/an/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Shattuck Labs, Inc., ALT is behind on 2 of 2 measures.
Against Shattuck Labs, Inc., ALT is behind on 2 of 2 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-06
Profit on each unit of sales-214861.0%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
Sales growth over five years-65.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
Debt against equityn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
Gross marginn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD
Price against earningsn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001326190-26-000018
- Reported in
- USD